GSK plc has received accelerated approval from the US Food and Drug Administration (FDA) for Nelkarmi (neladalkib), an ALK-selective Tyrosine Kinase Inhibitor (TKI), for the treatment of adults with locally advanced or metastatic Anaplastic Lymphoma Kinase (ALK)-positive Non-Small Cell Lung Cancer (NSCLC).
The approval covers patients whose disease has progressed following one prior ALK TKI, specifically alectinib, or those who have received two or more prior ALK TKIs and platinum-based chemotherapy in the unresectable locally advanced or metastatic setting. The decision was announced ahead of the FDA's original target action date of November 27, 2026, following the medicine's designation as a Breakthrough Therapy and an Orphan Drug.
The approval was based on results from the Phase 1/2 ALKOVE-1 trial, which evaluated neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumours. The primary efficacy analysis included 222 previously treated patients with ALK-positive NSCLC.
Among patients who had received alectinib as their only prior ALK TKI, the confirmed Overall Response Rate (ORR) was 49 percent (33 of 67 patients). Of the responders, 76 percent maintained a response for at least six months, while 52 percent had a Duration of Response (DOR) of at least 12 months.
In patients previously treated with two or more ALK TKIs and platinum-based chemotherapy, the confirmed ORR was 32 percent (50 of 155 patients). The duration of response was at least six months in 69 percent of responders and at least 12 months in 51 percent.
The trial also assessed intracranial responses among patients with measurable Central Nervous System (CNS) metastases at baseline. The intracranial ORR was 55 percent among patients previously treated with alectinib alone, including complete responses in 25 percent. In the group that had received two or more prior ALK TKIs and chemotherapy, the intracranial ORR was 26 percent, including complete responses in 11 percent.
The most common adverse reactions, occurring in at least 20 percent of patients, included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema and fatigue. Adverse reactions led to permanent discontinuation of treatment in 5 percent of patients, with hepatotoxicity being the most frequent reason.
According to GSK, neladalkib was developed to address treatment resistance and disease progression to the brain, two challenges associated with ALK-positive NSCLC. The medicine is designed to provide broad coverage of ALK resistance mutations, cross the blood-brain barrier and maintain target selectivity.
Nelkarmi, which became part of GSK's portfolio following its acquisition of Nuvalent, Inc., is also being evaluated in the ongoing Phase 3 ALKAZAR trial in patients with treatment-naïve ALK-positive NSCLC. Its development programme includes evaluation in other solid tumours.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy